English-language podcasts

The Line

Conservatives can't cope with Carney's wins

79 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

In the latest episode of The Line Podcast, recorded between November 5th and 6th, 2026, Matt Gurney and Jen Gerson are joined by special guest Stephanie Levitz of The Globe and Mail. This episode is also brought to you by Cameco. First up, a brief explainer: due to Jen's being at a conference, part of this episode was recorded earlier in the week, after the midterms, but before the Canadian federal budget had been released. To avoid ignoring one of the huge stories of the week, Matt recorded a special segment of the podcast on Friday, after Jen had left for her event. In that segment, Stephanie Levitz joins Matt for a quick discussion of the federal budget. What's in it, what's missing, and what does it tell us about the Carney government's priorities? They take stock of what Ottawa is promising, what it's actually prepared to spend money on, and what Canadians should take away from it all. This episode is also brought to you by BioCanRx. This month we’re addressing common questions, like: are immunotherapy technologies dual-use?While many immunotherapies are personalized using a patient’s own cells, the research and manufacturing infrastructure behind them can produce other important products, like vaccines. The people behind those research, manufacturing, and clinical delivery processes are also extremely capable and versatile. Greater support for translational research and clinical trials would help grow this workforce and build capabilities that extend well beyond cancer. In a health emergency, that capacity could also help Canada respond quickly to urgent needs for new treatments and vaccines. Visit BioCanRx.com (http://biocanrx.com/) to learn more. And then, as recorded earlier in the week, Matt and Jen have a lengthy discussion about the U.S. midterm elections and what they mean for Canada. They consider the political forces shaping the results, what the elections tell us about Donald Trump's America, and what Canadians should expect from Washington in the years ahead. Whatever happens in American domestic politics, Canada still has to figure out how to deal with a neighbour whose political priorities and relationship with the rest of the world have changed dramatically. Finally, your hosts pivot from the American midterms to how they're being received here in Canada. Jen breaks her own rule about not talking about the Conservatives and talks about the Conservatives. Matt, meanwhile, has a warning for some Canadian conservatives: he thinks they're having a hard time coming to grips with the fact that they're Liberals now. And the sooner they figure that out, the better. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. Like and subscribe! #TheLinePodcast #MarkCarney #FederalBudget2026 #CanadianPolitics #USMidterms #DonaldTrump #CanadaUSRelations #PierrePoilievre #ConservativeParty #CurrentAffairs

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from The Line

The Line

Carney sticks it to Putin ... but will food prices sink him?

69 min

In this episode of On The Line, host Matt Gurney is joined by two guests to discuss hockey, inflation, politics, and whether Canada can finally get serious about building major infrastructure. This episode is brought to you by BioCanRx. This month we’re addressing common questions, like: do these therapies have export potential? The farthest advanced BioCanRx-supported therapies are still in clinical trials here in Canada, but other countries are already expressing interest based on their efficacy and lower cost. Canadian-developed CAR-T technology from the CLIC group is already being used to treat clinical trial patients in Denmark, and other countries with high numbers of leukemia cases have expressed interest. A successful clinical trial in another country can be an important first step toward bringing that therapy to market there. If BioCanRx-supported therapies continue to be trialed outside Canada, it sends a strong signal that made-in-Canada immunotherapies will find a receptive

Discuss this episode

The Line

Carney's Immigration Fail

67 min

In the latest episode of The Line Podcast, recorded on November 13th, 2026, Matt Gurney is joined by Andrew Potter, filling in for Jen Gerson from Montreal. This episode is brought to you by Cameco. First up, your hosts tackle the immigration debate now exploding across Canada. Both are very mindful of the fact that they're middle-aged white dudes, but they have serious concerns about the government's new proposals. For one thing, the economic rationale simply isn't there. For another, the Liberals have done almost none of the political groundwork necessary to sell these changes to Canadians. As Andrew notes, this government, like most Liberal governments, hates having to explain itself to the public. Matt worries that the consequences could be severe. Canada has maintained a remarkable pro-immigrant consensus for decades, and while Canadians have clearly soured on immigration, they haven't yet soured on immigrants. That distinction matters. And it might not last. Next, Matt and Andrew

Discuss this episode

The Line

How Canada will fight, and who we'll let in

53 min

In this episode of On The Line, host Matt Gurney is joined by two guests to discuss what the federal budget tells us about Canada's plans for national defence, immigration, housing and the economy. This episode is brought to you by BioCanRx. This week we asked whether the new federal budget improves the landscape for Canadian drug development. Short answer: it does! New tax incentives will support Canadian biotech companies carrying out commercialization and regulatory activities in Canada, and federal research funding agencies will modernize to offer additional support for bridging lab to market. The government also pledged to respond to recommendations from last summer’s Pharmaceutical and Life Sciences Sector Task Force. Steps like these can address key challenges facing Canada's life-sciences sector and make Canada more globally competitive. There is much more work to do to support Canadian health-care systems. BioCanRx will continue to participate in any effort to strengthen Canad

Discuss this episode

Community Poll

Public sports funding should prioritize everyday participation over elite competition.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

One sibling did years of caregiving. Should they get more of the inheritance?

One sibling lives near an aging parent and handles appointments, errands, and emergencies. The others live far away, call regularly, and assume the nearby sibling will receive the same inheritance despite years of unpaid work.

When does family care become labor that should be repaid?

Explore this quandary